The residual-alert problem
Device AI got us part way there, but not all the way.
In an expert-adjudicated analysis of more than 2,600 ICM episodes across four manufacturers, a large share of what reached clinicians still wasn’t actionable, even on the newest AI-equipped devices.3
of transmitted episodes were non-actionable, even after the manufacturer’s own AI filtering.3
of transmitted episodes were non-actionable on devices without on-board AI filtering.3
of pause alerts were false positives caused by R-wave undersensing: the heart kept beating, the device just missed it.3
Better device filters shrink the pile. A second, independent layer catches more of what’s left.
Inside the workflow
A second read on every episode, in the place you already work.
Each residual episode comes with an Implicity suggestion next to the device’s own label. Try a few examples to see what that looks like for your team.
- One review standard for every brand. The same logic applies to every manufacturer’s loop recorders, so your clinic isn’t juggling five different definitions of a “pause.”
- Real events stay in front of you. The algorithm is built for high sensitivity, so it’s designed to clear noise without hiding the episodes that need you.
- No new hardware, no new portal. It runs inside the Implicity platform on the transmissions you already receive.
Illustrative examples. Not actual patient data or algorithm output; every episode is reviewed by your clinical team.
Clinical evidence
fewer false-positive ICM episodes, on top of manufacturer filtering, while maintaining high sensitivity.1
FAQ
Questions clinics ask us most.
What is the Implicity ILR ECG Analyzer†?
An FDA-cleared Class II software medical device† that reviews the ECG episodes implantable loop recorders (ICMs) send after the manufacturer’s own filtering. It suggests which ones are likely false positives, so clinicians can focus on clinically meaningful events.
Does it replace clinician review?
No. Results are advisory only. Every suggestion goes to a qualified healthcare professional, who accepts or changes it alongside their own clinical knowledge and other diagnostic information.†
Which loop recorders does it work with?
It is cleared for ICM ECG data from the following major manufacturers: Abbott, Biotronik, Boston Scientific and Medtronic.†
My ICMs already use AI. Why would I still see false positives?
Device filtering has improved, but a large share of the episodes that get through are still non-actionable. Pauses caused by R-wave undersensing are a common example.3 The ILR ECG Analyzer† works as a second layer on exactly those residual alerts.
When can my clinic use the next-generation algorithm?
Request a demo and we’ll walk you through the timing for your program.
- †IM007 ILR ECG Analyzer is an FDA-cleared Class II medical device (Manufacturer: Implicity), intended for qualified healthcare professionals for assessment of arrhythmias in implantable cardiac monitor (ICM) ECG data from the following major manufacturers: Abbott, Biotronik, Boston Scientific and Medtronic. It operates as a second-layer analysis of residual alerts remaining after manufacturer filtering. The next-generation algorithm received FDA 510(k) clearance in July 2026 and is now commercially available to U.S. customers. Not for use in life-supporting or sustaining systems or ECG monitor and alarm devices. Results are advisory only, in conjunction with physician knowledge and other diagnostic information. See the instructions for use for more information.
- 1Varma N, Wadhwa M, Lazarus A, Faedda G, Mabo P, Crespin E. Performance of a cloud-based AI solution for reducing false positive alerts in implantable cardiac monitors detected episodes. Europace. 2026;28(Suppl 1):euag105.043.
- 2Marijon E, Crespin E, Leclercq C, Faedda G, Mabo P, Barraud J, Varma N. PO-01-235: Performance of a new cloud-based AI solution reducing false positive alerts in implantable cardiac monitor episodes on top of manufacturer AI algorithms. Heart Rhythm. 2026;23(4 Suppl):S294-S295.
- 3Implicity-sponsored analysis presented at EHRA 2026: 2,659 ICM episodes from 1,710 patients with Medtronic, Biotronik, Abbott and Boston Scientific devices, adjudicated by an independent expert committee using a guideline-aligned annotation framework. Presented at EHRA 2026, Paris, France, 12–14 April 2026.
The Implicity platform is a clinical decision support device and is in no way intended to replace the responsibility or clinical judgment of the practitioner. It is designed to optimize data workflows and support medical expertise in patient management.

